Looking Beyond Oncology: Investigating Development & Delivery of AOCs Against Neuromuscular Disorders

• Exploring the FORCE modular drug delivery approach to enable widespread distribution of AOCs and chemically diverse therapeutic payloads to muscle and the CNS
• Assessing clinical data from DYNE-101 ACHIEVE trial in patients with DM1 and DYNE-251 DELIVER trial against DMD
• Contextualising how the encouraging clinical data and preclinical efficacy in FSHD and Pompe models supports the potential of FORCETM and AOCs to address neuromuscular disorders with high unmet medical needs

Speakers:

Nick Yoder

Executive Director

Dyne Therapeutics